OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2024-02-29-accounts

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 29TH FEBRUARY 2024

Charity number 1082082 Company number 03908709

INTERNATIONAL CANCER IMAGING SOCIETY

FINANCIAL STATEMENTS FOR THE YEAR ENDED 29TH FEBRUARY 2024

Contents Page
Report of the Trustees 1-9
Independent Examiner’s Report 10
Statement of Financial Activities 11
Balance Sheet 12
Notes to the Accounts 13-18

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024

The trustees (who are also the directors of the company) present their report and the independently examined financial statements of the charitable company for the year ended 29th February 2024.

The Board of Trustees is satisfied with the performance of the charity during the year, considers that the charity is able to continue its activities during the coming year and that the charity’s assets are adequate to fulfil its obligations.

The trustees who served during the year and to the date of this report were:

Prof. Dame Janet Husband Prof. Rodney Reznek Prof. Stefan Diederich Prof. Anwar Padhani Prof. Harriet Thoeny Prof. Dow-Mu Koh Prof. Andrea Rockall Dr. Beth McCarville Dr. Evis Sala Prof. Willem Oyen Dr. Rosemarie Forstner Dr. Giovanni Morana Dr. Aslam Sohaib Prof. Rodney Hicks Prof. Annick Van Den Abbeele Prof. Olivier Lucidarme Dr. Thierry Huisman Prof. Pek Lan Khong Prof. Giuseppe Petralia Prof. Anju Sahdev (appointed 23 October 2023)

The key management personnel are the trustees and Maureen Watts - General Manager.

Secretary and Registered Office Mr Trevor Pereira 41 Waddington Way London SE19 3UB

Registered Charity No: 1082082

Company Registration No: 03908709

Bankers Barclays Bank plc 9 Portman Square London W1A 3AL

Independent Jacob Cavenagh & Skeet Examiners 5 Robin Hood Lane Sutton Surrey SM1 2SW

Solicitors Weightmans LLP 100 Old Hall Street Liverpool L3 9QJ

Page 1

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

Objects and Activities to achieve a public benefit

The Society was incorporated on 18th January 2000 to advance education and research within the field of oncological imaging and human tumour behaviour worldwide including in particular:

The main activities undertaken by the Society to meet these objects are through like-minded engagement with oncologic societies and imaging teaching courses held through the year.

The Society has as its charitable purpose the advancement of health or saving lives, promoting as it does the sharing of information and latest developments within oncological imaging and tumour behaviour worldwide. The resulting benefit to the public is that attendees at teaching courses are able to put into practice the latest research, technologic developments and findings to improve the treatment and care given to cancer patients.

The trustees have referred to the guidance contained in the Charity Commission’s general guidance on public benefit when reviewing our aims and objectives and in planning future activities. In particular, the trustees consider how planned activities will contribute to the aims and objectives they have set.

Achievements and Performance

Whilst the direct impact of the pandemic had waned with worldwide travel re-established, a definite shift in delegate preference for online learning was observed and it was noted that both in-person and online educational activities should be offered to maintain the Society’s status worldwide.

The ICIS Interactive Masterclass workshop series in particular was affected by this shift and two new courses focusing on Head & Neck Cancers, and Current Topics in Renal & Adrenal Imaging, originally planned for classroom delivery, had to be postponed due to lack of registrations and re-scheduled for online delivery in November 2023 and January 2024 respectively. Other masterclass workshops conducted online during this period covered pancreatic malignancies, and whole-body MRI. A new initiative was trialled for the whole-body MRI workshop in conjunction with the South African Congress of Oncology (SACO), in Cape Town, with a hybrid delivery whereby one faculty member was onsite with the attendees and the other four faculty members joined via video link to present virtually. The workshop sold out very quickly and was very well-received by the onsite delegates; this model is likely to be repeated in the future. The Collective Minds Radiology (CMRAD) platform continued to be utilised for delivery of the masterclass workshops with an ongoing contract in place.

The postponed AI & Machine Learning 3.0 meeting was held in June 2023 in Lisbon, Portugal, in collaboration with the Champalimaud Foundation. Industry support was secured and a small exhibition included onsite which was well-received, and despite lower registration numbers than had been envisaged, a surplus was generated. This surplus will be ring-fenced with a view to exploring options for a future AI & Machine Learning meeting.

Page 2

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

The ‘Read with the Experts’ series launched in February 2023 focusing on hepatobiliary imaging continued with four further segments conducted, each curated by an ICIS Fellow, utilising the CMRAD platform. Registrants had access to review cases and answer MCQs before a webinar was conducted to reveal the correct answers and the diagnosis. Whilst the number of participants of each segment was far fewer than originally hoped, a regular group of supporters of this series emerged. Upon conclusion of the final segment, the results were collated and prizes awarded to the two who had achieved the highest scores.

It was agreed that the bi-monthly webinars should be re-established in 2024 to attract wider interest and to promote the Society’s educational activities globally. The first webinar in February 2024 was hosted jointly with an Australian prostate research consortium, providing an opportunity to promote the ICIS 2024 annual conference to be held in Singapore. The webinars remained free to watch live with subsequent posting in the ICIS members’ area of the website or uploaded to the Society’s YouTube channel.

The annual conference for 2023 was held in London, 25-27 September 2023, at the British Museum, London, utilising the deposit payment retained by the museum during the pandemic.

The meeting President, Professor Olivier Lucidarme, oversaw a successful three-day meeting, and whilst not on the scale of the previous annual conference held at the British Museum, very positive feedback was received from all participants and a significant financial surplus was generated.

Minimal activity with ICIS satellite meetings returned and in September 2023 five ICIS Fellows participated in the Korean Congress of Radiology (KCR), in Seoul. In addition, arrangements were confirmed for a joint session with the Taiwanese Radiological Society during the 22nd Asian Oceanian Congress of Radiology (AOCR 2024) to be held in March 2024 in Taiwan. A Society booth for ICIS will be included in the AOCR exhibition, which will enable promotion of the 2024 annual conference in Singapore. Satellite activities are considered an important part of the Society’s educational output to reach and teach colleagues around the globe; thus further potential partnerships with international contacts will be explored to restart a programme of collaborations.

The opportunity to attend the Radiological Society of North America 2023 Annual Scientific Meeting (RSNA) with a complimentary Society booth was relinquished due to the planned attendance at AOCR 2024; an application will be made for RSNA 2024.

Improving international visibility of the Society and worldwide marketing of Society events has remained under constant review. Regular social media activity through a range of platforms (‘X’, LinkedIn, Instagram, Facebook, and YouTube) has disseminated information, supporting the monthly e-newsletter, mailings and advertising. The ICIS website has been updated regularly, providing current and accurate information with the aim of increasing membership, attendance at teaching courses and readership of ‘Cancer Imaging’, all with a view to strengthening the Society’s profile, its outreach and influence, as well as generating income for the Society. All these channels enable dissemination of knowledge in oncological imaging and promote education and research in this specialist field.

‘Cancer Imaging’ has continued to be published by BioMed Central as an online open access journal. The Impact Factor (IF) released in June 2023 was a record 4.9, ranking the journal within the first quartile in Radiology journals (24/135) and second quartile in Oncology journals (78/241), producing a 5-year IF of 4.7. The number of articles accessed continued to increase throughout the year, surpassing 1 million during 2023.

Page 3

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

Professor Rodney Hicks [Melbourne, Australia] and Professor Annick Van den Abbeele [Boston, USA] continued as Joint Honorary Editors-in-Chief. Dr Thorsten Persigehl [Cologne, Germany] succeeded Professor Stefan Diederich [Dusseldorf, Germany] as Deputy Editor. Section Editors and the Editorial Board worked with the pool of submission reviewers to maintain this important work in a timely manner, supporting the Editors-in-Chief to develop ‘Cancer Imaging’ further.

Society membership levels were monitored regularly but remained lower following the overall impact of the pandemic. Considerable volume of free online content is now widely available, potentially reducing the worth of archived Society material accessed as member-only content. A limited increase was achieved during the registration period for the London annual conference but retaining members remained a challenge, likely to be impacted further when registrations are handled externally during organization of ICIS 2024 in Singapore.

At 29 February 2024, the number of Society members was 136 representing 35 countries worldwide; the number of Fellows was 87 and one Associate Fellow, representing 21 countries.

Structure, Governance and Management

The International Cancer Imaging Society is a company limited by guarantee, incorporated in England & Wales, and a registered charity, governed by its memorandum and articles of association.

The Society is governed by a Board of trustees that oversees the management of the activities which the charity runs. The charity trustees are also Directors of the Company limited by guarantee. Trustees are appointed by a vote of existing Trustees on the recommendation of a single Trustee. All Trustees with the exception of the treasurer have to be a Fellow of the Society.

The number of Trustees shall not be less than seven but shall not be subject to any maximum. Trustees remain in office for an initial term of six years. Trustees who indicate their willingness to do so, may continue in office for a subsequent term if this is agreed with other Trustees and Fellows.

Fellowship of the Society is restricted to physicians who have made a significant contribution to oncological imaging and are involved or interested in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any existing Fellow of the Society may apply to the Trustees to be considered for the status of Emeritus Fellow.

Associate Fellowship may be awarded to physicians who do not completely fulfil the criteria for Fellowship but are involved in the clinical practice, teaching or research of cancer radiology and devote at least half of their clinical working week to the care of cancer patients. Precise qualifications are not required although an applicant is expected to have considerable radiological experience and to be at a senior level. Any applicant for Associate Fellowship must be sponsored by at least one Fellow of the Society.

Membership of the Society is open to healthcare professionals with an interest in cancer imaging and in promoting the goals of the Society but who do not meet the criteria for Fellowship or do not wish to become a Fellow. Benefits of membership include reduced registration fees for Society teaching courses, access to the members’ area of the website with its expanding repository of recorded lectures and scientific posters and a 20% discount on the article processing charge for accepted publications in Cancer Imaging .

Page 4

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

During the period under review the Trustees convened on two occasions, online in March 2023 by virtual means, and in a hybrid format in September 2023, on the day before the commencement of the annual teaching course. Day to day decisions and activities of the Society are delegated by the Trustees to the Executive Board.

The Trustees proposed revision of the articles of association to permit a non-Fellow to be appointed as Chair of the Executive Board, to ensure continued leadership of the Executive Board. Voting by Fellows adopted this amendment which states in addition that a Deputy Chair be appointed from the Fellowship on occasion of a non-Fellow Chair, to provide appropriate support. A new Bye-Law was introduced to set out terms of governance for the Executive Board.

The Chair of the Executive Board reported to both Trustees’ meetings, outlining the Board’s ongoing work, including monitoring all Society activity and the work of the ICIS Secretariat. Meetings of the Executive Board were held in April, July and November 2023, and January 2024. These meetings were all conducted virtually enabling online participation of the internationally based Board members.

The Executive Board considers it judicious to maintain review of Society policies to ensure robust governance. The risk register is reviewed before each meeting to highlight any potential issues which could have a detrimental impact on the Society, identifying measures to mitigate and manage any risk.

The activity implemented by the three sub-committees set up to oversee the ICIS Interactive programme, e- learning, and social media and communications is reviewed at each Executive Board meeting, ensuring a focus on opportunities to develop key elements of Society activity. Consideration is also given to the benefits of Society membership with the intention of retaining existing and attracting new members.

Compliance with the General Data Protection Regulations (GDPR) is maintained in line with the UK General Data Protection Regulation (UK GDPR 2021), tailored by the Data Protection Act 2018, and subject to monitoring by the Society registration with the Information Commissioner’s Office.

Risks

Regular review of the risk register ensured continual monitoring of Society practices and activities to determine that anticipated benefit outweighed possible risk to the Society; maintaining income streams and promoting the Society worldwide remained a top priority. The proposed replacement of the Society website and admin system underwent thorough review, to establish the most suitable provider to undertake the project. The Society requires a viable, modern, robust structure from which to operate and expand, taking into account the financial implications or impact on Society reserves.

Continued global interest in online educational activity in a very competitive virtual environment remained a challenge and risk to the Society. The Society’s reputation as a provider of high-quality education on oncological imaging must be maintained; publication of high quality research articles and reviews in ‘Cancer Imaging’ has retained the journal’s international standing in its field. Enhancing the value of ICIS membership will mitigate the risk of lower member numbers, whose support is an integral element of the Society’s continued growth and success.

The Trustees have considered other possible risks the Society may be open to, and although the education is based within the very specialist field of oncology, the Trustees believe the study, analysis and promotion of research in this area does not open the Society itself to the risk of litigation from any third party. Commercial risks of operation include the running of the annual teaching course and the ICIS Interactive workshop series.

Page 5

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

The Executive Board continued to consider potential natural disasters, international instability and terrorism as part of planning for in-person Society teaching courses, including any risk posed by infectious diseases, such as variants of COVID-19, to report to the Trustees. The city and venue for each annual teaching course, or any in-person event, is chosen carefully with a request to include a break clause in the venue contract to mitigate potential risks should plans have to be changed. Insurance is reviewed every year.

The financial implications to the Society of any future satellite meetings will be carefully analysed to ensure that the Society is not exposed to additional financial risks, and the progress of ‘Cancer Imaging’ will be kept under regular review.

Reference and administrative details

The Secretariat comprises two part-time employees, supported by contractors, who together maintain full and proper administrative control of all Society activities. During the period under review, additional administrative support was secured to ease the pressure on the existing personnel.

Engagement of personnel continued with two-yearly renewable contracts, allowing for appropriate review, including salaries. ICIS does not have a central office facility for personnel, thus overhead running costs are reduced; the administrative team work individually remotely but maintain frequent virtual contact to provide efficient and timely attention to all matters.

The web management company engaged in July 2022 identified instability in the outdated Society IT systems, recommending replacement within 18 months to two years. A project commenced to undertake a detailed review of the Society’s requirements and invitations were put out to tender to companies considered suitable to undertake this important project. After thorough financial review of all proposals and due diligence, it is hoped that a replacement project will be started promptly with a view to completion by autumn 2024.

The Secretariat remained committed to enhancing engagement within the international radiology community to raise the profile of the Society, to encourage registration for teaching courses, to deliver successful courses and secure income for the continued functioning of the Society.

Financial Review

The Trustees and the Executive Board continued to monitor Society finances and financial reserves closely, with monthly review of management accounts undertaken by key personnel. Securing industry support for the Society and teaching activities in a less robust worldwide economic environment proved more challenging, whilst reduced income as a result of lower registration numbers created additional pressure on securing positive financial outcome.

The Society’s corporate sponsorship package aims to secure financial commitment to the Society by industry leaders, The Executive Board recommended that three-year commitment should be sought for each new contract negotiated, with a view to facilitating robust financial planning and forecasting.

Siemens Healthineers, a machine manufacturing company, continued their support. The agreement with Guerbet, a contrast media company, has not currently been renewed for 2024 following their increased level of support for the ICIS 2023 annual course secured by the ICIS 2023 President. Support from other companies may be explored as a second corporate sponsor would provide additional guaranteed income, to relieve some financial pressure.

Page 6

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

Following the successful implementation of selling online access to content recorded at the ICIS 2022 annual teaching course, this was repeated and content of ICIS 2023 was made available for purchase as an online package with access until September 2024. Income generated offset the cost of providing this content, generated a small surplus and served as a marketing tool for other Society activity.

Continued online delivery of the ICIS Interactive Masterclass series remained a valued source of income as preference was expressed by delegates for this format.

‘Cancer Imaging’ remained a notable element of the Society’s overall success. Royalty payments based on revenue from published articles and an incentive bonus payment dependent on achievement of predetermined targets both provided a beneficial income stream for the Society.

The Article Processing Charge (APC) is subject to annual review by the publisher. The Society has the option to apply a surcharge to the APC, the proceeds of which would provide direct additional income for the Society from each article published; however, it is judicious to consider the potential impact of a surcharge limiting the journal’s attractiveness to authors, thereby reducing the number of submissions.

The Trustees are pleased to report that the overall outcome to the year ending 29 February 2024 is an increase of Society reserves, re-establishing a strengthened financial position. This has been achieved through support secured from industry, income generated from the 2023 annual teaching course and continued online delivery of ICISi masterclass workshops, alongside the stringent approach to control of Society expenditure.

The Trustees will remain vigilant in overseeing Society activity and proposals for future income generation, and remain optimistic that continued development of activities and worldwide promotion of the Society will assure a long-term future for the Society.

Reserves Policy

The Trustees undertook a review of the Society’s reserve policy to ensure compliance with current Charity Commission guidance. The annual teaching course is the Society’s flagship event and primary income stream, representing significant financial undertaking for the Society. The Trustees remain committed to holding reserves sufficient to cover all potential costs in the event of a failed or aborted annual teaching course, and have agreed that reserves in the range of £200,000-£250,000 should be maintained. As the Trustees anticipate that the outturn to the 2024-25 financial year will be challenging, the availability of the reserves will help ensure the continuity of the Society. Additional requirement for reserves identified in this period included unforeseen costs associated with replacement of the Society website/administrative system, an investment required to ensure future stability. Furthermore, the continued decline in industry support due to worldwide economic factors could necessitate use of reserves to maintain Society functions with potential increase in staff costs if additional cover were needed to support the small team.

The Society had unrestricted reserves of £395,911 that were not invested in fixed assets at the year end to February 2024; (2023: £318,808).

Page 7

INTERNATIONAL CANCER IMAGING SOCIETY

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

Plans for the future

On behalf of the Trustees, the Executive Board and sub-committees work to improve and expand the educational portfolio of the Society, to reach colleagues in the radiology community internationally and generate financial stability to permit further growth and development. The annual teaching course and the ICIS Interactive Masterclass workshop series are two key components of this strategy, in addition to attracting industry support, generating sufficient income to sustain the administrative structure and maintain reserves.

The Executive Board has agreed that a combination of in-person and online courses provides the best balance of educational activity, and this balance will be maintained when programming future events, taking into account continued global economic pressures.

With the President for the annual teaching course in 2024 based in Singapore, the Trustees reviewed the proposal to conduct the first Asian annual conference. A collaboration agreement with the Singapore Radiological Society and College of Radiologists Singapore was signed to jointly organize and hold the annual conference in Singapore in September 2024. It was agreed that this joint venture would serve to introduce the Society to a new region and potentially establish links with other societies for future collaborations.

Entitled ‘ICIS SGCR-WIRES 2024’ to acknowledge the collaboration, the theme of the meeting will be ‘Illuminating Cancer Care: The evolving role of imaging and intervention in modern clinical practice’. The multidisciplinary programme will be planned to provide valuable updates and insights for the international radiological, nuclear medicine and allied health communities, including the latest research and developments, highlighting the specialist field of cancer imaging and intervention.

Following an invitation from Siemens Healthineers, plans are in place to conduct the ICIS Interactive Masterclass on Gynaecological Cancers at their Academy facility in Warsaw, Poland, in May 2024. Other masterclasses have been held there successfully in the past and if well-received on this occasion, further courses will be scheduled. The ever-popular Masterclass in Whole-Body MRI will be held online in July 2024; a venue in central Stockholm is under review to potentially repeat this course in a classroom setting later in 2024. In 2025 the Masterclass in Head & Neck Cancers will be delivered online for the second time.

Discussions to assess feasibility of other new masterclass workshop topics include thoracic, hepatobiliary and rectal cancers; these new courses may be developed for delivery in 2025/2026.

A further ICIS in Focus meeting covering Artificial Intelligence and Machine Learning in Cancer Imaging may be considered for 2025, pending review of suitable venues. Ring-fenced funds following the 2023 ICIS in Focus course are available to support this initiative.

The Trustees have agreed that the 2025 annual teaching course should return to Europe; the preferred location has been confirmed as The Hague, in The Netherlands.

The series of bi-monthly webinars covering a variety of topics, planned by the e-learning committee, will continue as these generate substantial audiences with a wide geographical spread. Collaborations with other societies are considered to broaden the reach and establish relationships for future joint ventures.

A collaboration under the guidance of a Memorandum of Understanding with the Brazilian Radiological Society (SPR) is under review with initial plans to organize regular joint scientific sessions as part of respective annual teaching courses. Similar collaborations with other international partners may be explored to expand the Society’s worldwide reach.

Page 8

INTERNATIONAL CANCER IMAGING SOCIETY REPORT OF THE TRUSTEES FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued) It is hoped that opportunities can be explored to establish further satellite meetings from 2025. These meetings present an opportunity to enhance the international profile of the Society, and enable radiologists in locations otherwise unable to attend ICIS teaching courses to benefit from the knowledge and expertise of the ICIS Fellows. The possibility of linking virtually with previous satellite partners may be explored, but potential online fatigue versus the value of in-person meetings will be factored into any decision. An appraisal of any proposed satellite venue is reported to the Trustees to ensure no financial risk is posed to the Society, and Fellows representing the Society are not exposed to any personal risk. The Society does not cover any speaker expenses,. these costs must be met by the host societies or personally. Marketing Society activities and 'Cancer Imaging, will remain a priority., electronic means and social media enable enhanced communication with members and the wider international community with an interest in oncological imaging. The benefits of membership will be reviewed and assessment of options presented by nline education to assist in promoting the Society and enhancing the appeal of membership. Google analytics of traffic to the ICIS website permits review of activity and the number of members will continue to be monitored regularly. Electronic surveys allow a quick and efficient method of communicating and provide engagement with membership and course delegates to seek valuable opinion. With the introduction of a new IT system, website analytics should be enhanced to inform on current activity and future developments. A review of the overall Society strategy will be undertaken in late 2024 12025 to establish that Society activities and plans are relevant for the current requirements and expectations of the International radiological community and those embarking on a career in this specialist field. By order of the Board on 26 September 2024 Trevor Pereira Secretary Page 9

INDEPENDENT EXAMINER'S REPORT TO THE TRUSTEES OF INTERNATIONAL CANCER IMAGING SOCIETY I report to the charity trustees on my examination of the accounts of the Company for the year ended 29th February 2024 set out on pages 11 to 18. Responsibilities and basis of report As the charity's trustees (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act,). Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charites Act 2011 ('the 2011 Act,). In carrying out my examination I have followed the directions given by the Charity Commission under section 145(5)(b) of the 2011 Act. Independent examiner's statement I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act., or the accounts do not accord with those records., or the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view, which is not a matter considered as part of an independent examination., or the accounts have not been prepared in accordance with the methods and principles of Accounting and Reporting by Charities.. Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached. Paul Newton FCA Jacob Cavenagh & Skeet 5 Robin Hood Lane Sutton Surrey SM1 2SW Date: 1£ Octhc ZoL(fr Page 10

INTERNATIONAL CANCER IMAGING SOCIETY

STATEMENT OF FINANCIAL ACTIVITIES (incorporating the income and expenditure account) FOR THE YEAR ENDED 29TH FEBRUARY 2024

2024
Unrestricted
Restricted
Funds
Funds
Note
£
£
Income from:
Charitable activities
Conference sponsorship and funding
118,340
29,782
Revenue from conference delegates
146,938
-
Membership income
15,577
-
ICIS Interactives
30,504
-
Journal income
32,895
-
Interest receivable
4,763
-
Total income
349,017
29,782
Expenditure on:
Charitable activities
2
272,066
16,712
Total expenditure
272,066
16,712
Net income/(expenditure) and movement in funds
76,951
13,070
Reconciliation of funds
Total funds brought forward
319,414
-
Total funds carried forward
396,365
13,070
The notes on pages 13 to 18 form part of these financial statements.		 2024 Total
£
148,122
146,938
15,577
30,504
32,895
4,763
378,799
288,778
288,778
90,021
319,414
409,435		 2023

Page 11

INTERNATIONAL CANCER IMAGING SOCIETY BALANCE SHEET AS AT 29TH FEBRUARY 2024 2024 2023 Note Fixed assets Tangible fixed assets 454 606 Current assets Debtors Cash at bank and in hand 41,871 393 118 434,989 37,506 308 446 345,952 Creditors. Amounts falling due within one year 26 008 Net current assets 408 981 318 808 Total Net assets less current liabilities Funds Unrestricted funds Restricted funds 396,365 319,414 Total Funds These accounts have been prepared in accordance with the provisions available to companies subject to the small companies, regime within Part 15 of the Companies Act 2006. For the financial year ended 29 February 2024 the company was entitled to exemption from audit under section 477 Companies Act 2006. No member of the company has deposited a notice, pursuant to section 476, requiring an audit of these financial statements under the requirements of the Companies Act 2006. The directors acknowledge their responsibilities for ensuring that the company keeps accounting records which comply with section 386 of the Act and for preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of the financial year and of its surplus or deficit for the financial year in accordance with the requirements of sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to accounts, so far as applicable to the company. The financial statements were approved by the Board on 26 September 2024 and signed on their behalf by Dr. Aslam Sohaib Trustee Prof. Dow Mu Koh Trustee Registered Charity No: 1082082 Company Registration No: 03908709 The notes on pages 13 to 18 form part of these financial statements. Page 12

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 29TH FEBRUARY 2024

1 ACCOUNTING POLICIES

(a) Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with the Companies Act 2006, applicable accounting standards and with the Statement of Recommended Practice (Charities SORP (FRS 102)) and Financial Reporting Standard 102 (FRS 102). The financial statements are prepared in pounds sterling rounded to the nearest pound.

International Cancer Imaging Society meets the definition of a public benefit entity under FRS 102. The Society is a company limited by guaranteed registered in England & Wales with its registered office at 41 Waddington Way, London, SE19 3UB.

(b) Going concern

There are no significant uncertainties about the charity’s ability to continue as a going concern.

(c) Income recognition

Donations and other income are included in the Statement of Financial Activities (SOFA) when the charity has entitlement to the income, it is probable the income will be received and the amount of income receivable can be reliably measured.

Revenue grants are accounted for on an accruals basis, matching it to the actual projects undertaken in the period rather than uniformly over the grant period.

Income received from delegates and sponsors for courses are recorded in the year the course takes place.

(d) Expenditure recognition

All expenditure is accrued as soon as a liability is considered probable, discounted to present value for longer term liabilities and has been classified under headings that aggregate all costs related to the category

Charitable activities comprise expenditure directly related to the objects of the charity, including administration and support functions including any related provisions. It also includes governance costs, which comprise expenditure to comply with statutory and legal requirements

(e) Irrecoverable VAT

Irrecoverable VAT is included with the expense upon which it is incurred.

(f) Transactions in foreign currencies

Transactions in foreign currencies are translated into sterling at the exchange rate ruling at the date of the transaction. Assets and liabilities at the balance sheet date are translated into sterling at the rate ruling at the balance sheet date. All resultant differences arising from the above policy are dealt with in the Statement of Financial Activities.

(g) Tangible fixed assets

Tangible fixed assets are depreciated at the following annual rates:

Computer equipment – 25% (reducing balance basis)

Page 13

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

1 ACCOUNTING POLICIES (CONTINUED)

(h) Cash at bank and in hand Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of opening of the deposit.

(j) Financial instruments

The charity only has financial assets and liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value.

Page 14

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

2 EXPENDITURE ON CHARITABLE ACTIVITIES

Unrestricted
Restricted
Funds
Funds
£
£
Expenditure on
Charitable activities
Conference costs
85,916
9,950
Design, production and advertising
6,094
150
Administration
- Data Manager
-
-
- Staff costs (see note 9)
71,195
2,031
- Secretarial Services
6,665
1,700
- Other
2,500
-
Pension Scheme
284
-
Travel and accommodation
7,083
2,655
Printing
4,473
226
Bank charges and credit card charges
3,999
-
Gifts and donations
1,185
-
Insurance
654
-
Accreditations
353
-
Utilities
171
-
Postage/delivery charges
2,472
-
Telephone
525
-
Depreciation
152
-
Software expenses
1,119
-
IT support
27,885
-
Miscellaneous
-
-
Rent
1,020
-
Licenses and Permits
7,544
-
Subscriptions
-
-
Accounting
39,889
-
Professional Fees
504
-
Consultancy Fee
-
-
Independent Examiners fees
2,205
-
Foreign exchange losses/(gains)
(1,821)
-

272,066
16,712		 Total
2024
£
95,866
6,244
-
73,226
8,365
2,500
284
9,738
4,699
3,999
1,185
654
353
171
2,472
525
152
1,119
27,885
-
1,020
7,544
-
39,889
504
-
2,205
(1,821)

288,778		 Total
2023
£
190,472
7,421
4,120
72,560
8,972
2,500
335
15,806
6,377
2,601
100
1,773
435
226
529
577
202
1,805
12,033
835
977
553
13
38,918
2,124
300
2,079
(14,104)
360,539

Page 15

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

3 TANGIBLE FIXED ASSETS
Computer Total
Equipment
£ £
Cost
As at 1st March 2023 1,150 1,150
Additions - -
Disposals - -
As at 29th February 2024 1,150 1,150
Depreciation
As at 1st March 2023 544 544
Charge for year 152 152
Disposals - -
As at 29th February 2024 696 696
Net book value
As at 29th February 2024 454 454
As at 28th February 2023 606 606
4 DEBTORS
2024 2023
£ £
Trade debtors 8,975 22,820
Prepayments and accrued income 32,896 14,686
41,871 37,506
5 CREDITORS
2024 2023
£ £
Trade creditors 2,021 1,899
Accruals and deferred income 23,987 25,245
26,008 27,144
Deferred income is included within:
Current liabilities - 6,364
Movement in the year:
Deferred income at 1stMarch 2023 6,364 145,153
Released from previous periods ( 6,364) (145,153)
Resources deferred in the year - 6,364
Deferred income at 29th February 2024 - 6,364

Page 16

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

6
UNRESTRICTED FUNDS
At
1st March
2023
£
Unrestricted Funds
General Fund
319,414
At
1st March
2022
£
Unrestricted Funds
General Fund
358,548
7
RESTRICTED FUNDS
At
1st March
2023
£
Restricted Funds
AI Meeting
-		 Total
Total
At
Income
Expenditure
29th February
2024
£
£
£
349,017
(272,066)
396,365
Total
Total
At
Income
Expenditure
28th February
2023
£
£
£
321,405
(360,539)
319,414
Total
Total
At
Income
Expenditure
29th February
2024
£
£
£
29,782
(16,712)
13,070

AI Meeting

This relates to funds received for the AI Meetings that started in 2023.

8 ANALYSIS OF NET ASSETS BY FUND

2024
Unrestricted
Restricted
£
£
Tangible fixed assets
454
-
Net current assets
395,911
13,070
396,365
13,070
2023
Unrestricted
Restricted
£
£
Tangible fixed assets
606
-
Net current assets
318,808
-
319,414
-		 Total
£
454
408,981
409,435
Total
£
606
318,808
319,414

Page 17

INTERNATIONAL CANCER IMAGING SOCIETY

NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 29TH FEBRUARY 2024 (continued)

9 STAFF COSTS

Salaries
Pension
Social security
Average no. staff		 2024
£
69,444
1,709
2,073
73,226
2		 2023
£
68,585
1,667
2,308
72,560
2

No employee earned over £60,000 in the year, nor in the previous financial year.

The total employee benefits of the key management personnel of the charity as listed on page 1 were £47,355 (2023: £49,505). There were no other related party transactions in the year.

10 TRUSTEES’ REMUNERATION

None of the trustees received any remuneration from the charity during the year (2023: none). Travel expenses incurred on behalf of the Society and reimbursed during the year to 29th February 2024 related to one trustee and amounted to £1,500 (2023: £nil).

In accordance with the Articles of Association, the Trustees may be paid all reasonable travelling, hotel and other expenses properly incurred by them in connection with their attendance at meetings of Trustees or committees of Trustees or general meetings or otherwise in connection with the discharge of their duties, but shall otherwise be paid no remuneration.

11 LIMITED BY GUARANTEE

The company is limited by guarantee, each member (termed “Fellow” from October 2004) having guaranteed to pay £1 should the company be wound up.

Page 18